Analyse
The claim aligns with extensive research (e.g., WHO, World Bank, Lancet Commission) demonstrating that proactive health investments—such as vaccination programs, pandemic preparedness, and primary care—yield high economic returns by reducing outbreak costs, improving productivity, and lowering long-term treatment expenses. **However**, the statement oversimplifies complex trade-offs: some preventive measures (e.g., overbuilding hospital capacity in low-risk regions) may not always outperform reactive spending, and cost-benefit ratios vary by country income level, disease burden, and system efficiency. The framing as an unequivocal rule ignores cases where short-term fiscal constraints or misallocation of funds could undermine the claimed benefits.
Achtergrond
The WHO has long advocated for health systems strengthening as a cornerstone of global security, citing estimates that every $1 spent on pandemic preparedness saves $4–$6 in emergency response costs (World Bank, 2019). Ghebreyesus’ remark echoes the 2001 *Macroeconomics and Health* report and later SDG agendas, which position health as both a moral imperative and an economic catalyst. Critics, however, note that such investments often compete with immediate priorities (e.g., debt servicing, education) in resource-limited settings.
Samenvatting verdict
The statement reflects widely accepted economic and public health principles, but its absolute framing as a universal truth lacks empirical precision for *all* contexts.